These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34534674)

  • 1. 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors.
    Kanada R; Suzuki T; Murata T; Miyazaki M; Shimada T; Kuroha M; Minami M; Higuchi S; Tominaga Y; Naito H
    Bioorg Med Chem Lett; 2021 Nov; 51():128358. PubMed ID: 34534674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
    Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
    Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
    Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
    J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors.
    Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE
    ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
    Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
    Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.
    Conery AR; Centore RC; Neiss A; Keller PJ; Joshi S; Spillane KL; Sandy P; Hatton C; Pardo E; Zawadzke L; Bommi-Reddy A; Gascoigne KE; Bryant BM; Mertz JA; Sims RJ
    Elife; 2016 Jan; 5():. PubMed ID: 26731516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
    Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H
    J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.
    Ji Z; Clark RF; Bhat V; Matthew Hansen T; Lasko LM; Bromberg KD; Manaves V; Algire M; Martin R; Qiu W; Torrent M; Jakob CG; Liu H; Cole PA; Marmorstein R; Kesicki EA; Lai A; Michaelides MR
    Bioorg Med Chem Lett; 2021 May; 39():127854. PubMed ID: 33631370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors.
    Furdas SD; Shekfeh S; Bissinger EM; Wagner JM; Schlimme S; Valkov V; Hendzel M; Jung M; Sippl W
    Bioorg Med Chem; 2011 Jun; 19(12):3678-89. PubMed ID: 21353783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and molecular modelling studies of novel 3-acetamido-4-methyl benzoic acid derivatives as inhibitors of protein tyrosine phosphatase 1B.
    Rakse M; Karthikeyan C; Deora GS; Moorthy NS; Rathore V; Rawat AK; Srivastava AK; Trivedi P
    Eur J Med Chem; 2013; 70():469-76. PubMed ID: 24185377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition.
    Shendy NAM; Bikowitz M; Sigua LH; Zhang Y; Mercier A; Khashana Y; Nance S; Liu Q; Delahunty IM; Robinson S; Goel V; Rees MG; Ronan MA; Wang T; Kocak M; Roth JA; Wang Y; Freeman BB; Orr BA; Abraham BJ; Roussel MF; Schonbrunn E; Qi J; Durbin AD
    Nat Commun; 2024 Apr; 15(1):3483. PubMed ID: 38664416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel phosphatidylcholine-specific phospholipase C drug-like inhibitors as potential anticancer agents.
    Eurtivong C; Pilkington LI; van Rensburg M; White RM; Brar HK; Rees S; Paulin EK; Xu CS; Sharma N; Leung IKH; Leung E; Barker D; Reynisson J
    Eur J Med Chem; 2020 Feb; 187():111919. PubMed ID: 31810783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma.
    Ryan KR; Giles F; Morgan GJ
    Eur J Haematol; 2021 Jan; 106(1):90-99. PubMed ID: 32997383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
    Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.
    Kanada R; Kagoshima Y; Asano M; Suzuki T; Murata T; Haruta M; Takahashi M; Ubukata O; Hashimoto K; Obata K; Kihara K; Kuroha M; Banjo T; Togashi N; Sato K; Yamamoto Y; Suzuki K; Isoyama T; Tominaga Y; Higuchi S; Naito H
    Bioorg Med Chem Lett; 2022 Jun; 66():128726. PubMed ID: 35413416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological evaluation and molecular docking studies of indeno [1, 2-c] pyrazol derivatives as inhibitors of mitochondrial malate dehydrogenase 2 (MDH2).
    Ahmadi F; Engel M; Baradarani MM
    Bioorg Chem; 2021 May; 110():104779. PubMed ID: 33689977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.